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Introduction: The incidence of well differentiated thyroid cancer (WDTC) is rising in the USA. The
objective of this study is to present the changes in incidence, presentation, management and outcomes of
WDTC within our institution over the past 8 decades.
Methods: 2797 patients managed between 1932 and 2005 at Memorial Sloan Kettering Cancer Center
were identiﬁed from our institutional database.
Results: There has been an increase in the number of patients managed per decade. Although the median
age was 45 years, patients managed post-1985 were more likely to be over 45 years (53% versus 44%,
p < 0.001). The percentage of women increased from 68% to 72% (p ¼ 0.026), and the percentage of
papillary carcinomas also increased, from 78% to 92%, p < 0.001. An increase in early stage tumors was
observed with pT1 lesions increasing from 19% to 48%. Patients in the latter cohort were less likely to
have thyroid lobectomy (29% versus 72%, p < 0.001). There was a signiﬁcant change in the use of RRA,
with 8% of the early versus 44% of the latter group receiving post-operative RRA (p < 0.001). Since the
introduction of risk group stratiﬁcation disease speciﬁc survival (DSS) has not changed signiﬁcantly. With
a median follow up of 90 months, 10 year DSS rates were below 90% in the cohort managed prior to the
1970s, which rose to >95% thereafter (p < 0.001).
Conclusions: Older patients with earlier stage disease present an increasing workload for surgical
oncologists. Excellent outcomes remain unchanged despite increasingly aggressive surgical and medical
management.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Well differentiated thyroid cancer (WDTC) is rising in incidence
in the USA and across the world over the past three decades.1e5
Unlike most human malignancies, WDTC has high cure rates
when managed appropriately.6e8 Our understanding of the biology
of this common disease and the impact of treatment on patient
outcome has evolved over the past century. Over this time period,
management of thyroid cancer has evolved from a wide spectrum
of treatment approaches to a more standardized evidence based
approach, due to improved understanding of the biological
behavior of this cancer, and supported by national andNixon), ganlyi@mskcc.org
rf@mskcc.org (F.L. Palmer),
@mskcc.org (R. Ghossein),
kcc.org (A.R. Shaha), shahj@
ciates Ltd. Published by Elsevier Ltinternational guidelines.9e11 Surgery remains the cornerstone of
management of thyroid cancer with post-operative radioactive
iodine administered as adjuvant treatment in selected cases based
on risk of recurrence and risk of disease speciﬁc mortality.
The objective of our study is to present the changing trends in
the incidence, presentation, management and outcomes of WDTC
within our institution over the past 8 decades.
2. Patients and methods
Following approval by the Institutional Review Board, 2797 patients who had
thyroid surgery for WDTC between 1932 and 2005 at Memorial Sloan Kettering
Cancer Center, New York, were identiﬁed from our institutional database. Data
collectionwas carried out over two separate time periods, with reports based on the
initial cohort (1932e1985, n¼ 987) published separately from the subsequent group
(1986e2005, n ¼ 1810). Both cohorts were combined to produce the data presented
in this manuscript. Patients with anaplastic, poorly differentiated and medullary
carcinoma, as well as those who were selected as not suitable for surgery were
excluded from these studies.
Data collected included patient demographics, surgical details including extent
of thyroid surgery, histopathological diagnosis at the time of treatment and pTNM
status. Data on adjuvant radioactive iodine remnant ablation (RRA) was alsod. All rights reserved.
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this manuscript we present data on 10 year disease speciﬁc survival (DSS). Mode of
death was determined from case notes and death certiﬁcates where available, and
cross checked against the social security index for all patients. Patients who were
known to have died of disease were coded as cause speciﬁc death. Thosewho died of
other causes were censored at the time of death for DSS analysis. Patients who died
during follow up, and no cause could be conﬁrmed were considered to have died of
disease if there was evidence of disease at last follow up, in order not to underes-
timate the effect of disease.
Our institutional approach to the management of WDTC involves risk stratiﬁ-
cation using the previously reported GAMES criteria (Table 1).13 These criteria,
consider patient and tumor factors in risk stratiﬁcation. This classiﬁcation was
designed to predict the risk of death fromWDTC, rather than the risk of recurrence.
Patients are considered at low risk if under the age of 45 years, and high risk if over
45 years. Tumors withmore aggressive histology, which are larger than 4 cm, and/or
have extrathyroid extension or have distant metastases are considered high risk
tumors. In contrast, well differentiated tumors that are less than 4 cm, and are
intrathyroidal, and have no evidence of distant metastases are considered low risk
tumors. Thus, patients above 45 years of age with high risk tumors are considered in
the high risk group. Patients under the age of 45, with low risk tumors are included
in the low risk group. All others are included in the intermediate risk group. i.e.
young patients with high risk tumors or older patients with low risk tumors.
Our philosophy of management has been to advocate ipsilateral lobectomy in
low risk patients with a unifocal intraglandular tumor, without any detectable
abnormality in the opposite lobe. Assessment of the contralateral lobe is by intra-
operative examination. Nowadays, this is supplemented with preoperative ultra-
sound. These patients do not receive RRA therapy. In the high risk group, a total
thyroidectomy or even more extensive resection and post-operative RRA is rec-
ommended. Surgical resection of all clinically apparent disease is the mainstay of
treatment and to this end extracapsular total thyroidectomy is performed with
resection of strap muscles, recurrent nerve and even laryngotracheal or esophageal
structures as indicated to ensure macroscopic surgical clearance. For intermediate
risk cases, an individualized treatment decision is made based on discussion
between the surgeon, endocrinologist and patient and is mainly based on tumor
factors. This approach to risk stratiﬁcation and treatment was adopted during the
time period of the initial cohort and has remained our standard of care for subse-
quent decades.
In terms of management of the neck, we do not perform routine elective central
or lateral compartment neck dissection. The cervical nodal basins are examined
clinically, ultrasonographically (in more recent years) and intra-operatively. For
a clinically positive neck, with palpable node in the lateral compartment, an
anatomically comprehensive, and oncologically effective selective neck dissection
(lymph nodes at levels II, III, IV and V) is carried out. If suspicious nodes are iden-
tiﬁed during surgery of the primary tumor, frozen section is used to conﬁrm
metastatic disease, and appropriate neck dissection is carried out depending on the
location of the metastatic nodes. Central compartment dissection is performed only
if suspicious nodes are noted during thyroidectomy and conﬁrmed by frozen section.
Statistical analysis was carried out using JMP statistical package (SAS Institute
Inc. SAS Campus Drive, Cary, NC 27513) and SPSS (IBM Company Headquarters,
233 S. Wacker Drive, 11th Floor, Chicago, Illinois 60606). Variables were compared
within groups using Pearson’s Chi squared test. Survival outcomes were determined
using the KaplaneMeier method. Univariate analysis was carried out by the log rank
test.3. Results
Patient, tumor and treatment characteristics of the group as
awhole and stratiﬁed by the date of initial surgical management by
decade are shown in Table 2. The median follow up for the overall
group was 90 months (range 1e811 months). Throughout the time
period studied, there has been a steady increase in the number ofTable 1
GAMES risk of cause speciﬁc mortality stratiﬁcation.
Risk level Patient factor Tumor factor
Low risk Age <45 y Papillary Ca M0 No ETE Size <4 cm
High risk Age >45 y Follicular Ca
/Hurthle
cell Ca








Low risk patient High risk tumor
High risk patient Low risk tumor
High risk case High risk patient High risk tumorpatients managed per decade, with 982 patients managed between
1932 and 1985 in comparison to 1810 patients between 1986 and
2005 (Table 2, Fig. 1).
The median age of the whole group was 45 years (range 4e94
years). In comparison with the earlier cohort, patients managed
post 1985 were more likely to be over the age of 45 years (53%
versus 44%, p < 0.001).
The percentage of women in the cohort increased from 68% to
72% in the more recent cohort (p ¼ 0.026), and the percentage of
tumors classiﬁed as papillary carcinoma also increased from 78% to
92%, p < 0.001.
An increase in early stage tumors was observed during the study
with pT1 lesions increasing from 19% in the early cohort to 48% in
the latter cohort. For pT4 tumors, representing locally advanced
tumors, we saw no increase in incidencewith 8% in the early cohort
and 7% in the latter cohort.
Throughout the decades there has been a rise in the percentage
of papillary carcinomas presenting with our institution. In the
earlier cohort, around 75% of WDTC were classiﬁed a papillary
carcinoma, which rose to 86% between 1986 and 1995 and 94%
between 1996 and 2005. This corresponded with a fall in the
percentage of follicular carcinomas from 18% to 3% over the same
time period. In part, this changemay be explained by changes in the
deﬁnition of follicular carcinoma, with some patients now being
classiﬁed as follicular variant of papillary carcinoma.
The percentage of patients with pathologically positive neck
nodes fell from 48% to 33% (p < 0.001). The incidence of patients
with distant metastasis at presentation was similar (4% in the early
versus 3% in the later cohort, p ¼ 0.262). The rising age of patients
resulted in an increased percentage of intermediate risk cases in the
later cohort, and a reduced number of low risk cases. However, the
number of cases considered high risk remained relatively constant
(Table 4a).
Trends in treatment revealed that patients in the later cohort
were less likely to have thyroid lobectomy (29% versus 72%,
p < 0.001), with a corresponding increase in rates of total
thyroidectomy. There was also a signiﬁcant change in the use of
RRA, with 8% of the pre 1985 group versus 44% of the post 1985
group receiving post-operative RRA (p < 0.001). When stratiﬁed by
decade, the percentage who received RRA rose from 0% in 1932e
1945 to 2%, 8%, 32%, 71%, 48% and 68% by 1996e2005.
By the 1970s, evidence had shown that procedures which
involved less than unilateral lobectomy resulted in worse
outcomes, and therefore for analysis of DSS we considered 3
groups: those managed before 1970, those managed between 1970
and 1986 and those managed between 1986 and 2005. Analysis of
DSS by time period shows a signiﬁcant improvement over time
with modern day 10 year survival ﬁgures of 96.1% (Table 3). This
improvement in outcome is most marked in the high risk group
(Table 4b). Since the introduction of risk group stratiﬁcation, and
individualized treatment protocols based on such an approach
(around the 1970s) DSS has not changed signiﬁcantly. 10 year DSS
rates were below 90% in the cohort managed prior to the 1970s,
which rose to >95% thereafter (p < 0.001).
Analysis of factors predictive of poorer outcome for the whole
group conﬁrmed non-papillary histology, age over 45 years, the
presence of distant metastasis, evidence of extrathyroid extension
and size over 4 cm as independent predictors on multivariate
analysis (GAMES).14 In contrast, the presence of lymph node
metastases was not predictive of DSS (Table 5).
4. Discussion
Over the past century there has been a gradual change in the
management of thyroid cancer. A number of major centers have
Table 2
Descriptive statistics of whole group and stratiﬁcation by decade.
Variable Group 1932e1945 1946e1955 1956e1965 1966e1975 1976e1985 1986e1995 1996e2005 p Value
Age <45 31 (47%) 142 (59%) 98 (56%) 135 (53%) 143 (57%) 242 (53%) 605 (45%) <0.001
>45 35 (53%) 100 (41%) 77 (44%) 119 (57%) 107 (43%) 212 (47%) 751 (55%)
Gender Female 41 (62%) 170 (70%) 119 (68%) 177 (70%) 161 (64%) 324 (71%) 974 (72%) 0.201
Male 25 (38%) 72 (30%) 56 (32%) 77 (30%) 89 (36%) 130 (29%) 382 (28%)
Procedure Lobe 52 (79%) 180 (74%) 133 (76%) 171 (67%) 171 (68%) 223 (49%) 293 (22%) <0.001
Isthmus 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (1%) 14 (1%)
Subtotal 2 (3%) 4 (2%) 5 (3%) 15 (6%) 6 (2%) 24 (5%) 13 (1%)
Total 11 (17%) 58 (24%) 37 (21%) 68 (27%) 73 (29%) 202 (45%) 1033 (76%)
Unresectable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (<1%)
Histology Papillary 50 (76%) 199 (82%) 138 (79%) 197 (78%) 191 (76%) 391 (86%) 1277 (94%) <0.001
Hurthle cell 4 (6%) 14 (6%) 12 (7%) 12 (5%) 14 (6%) 17 (4%) 42 (3%)
Follicular 12 (18%) 29 (12%) 25 (14%) 45 (18%) 45 (18%) 46 (10%) 37 (3%)
pT Stage T1 12 (18%) 46 (19%) 42 (24%) 35 (14%) 52 (21%) 191 (43%) 664 (49%) <0.001
T2 29 (44%) 136 (56%) 90 (51%) 187 (74%) 159 (64%) 99 (22%) 233 (17%)
T3 17 (26%) 41 (17%) 27 (15%) 24 (9%) 12 (5%) 119 (27%) 373 (28%)
T4 8 (12%) 19 (8%) 16 (9%) 8 (35) 26 (10%) 35 (8%) 86 (6%)
Micro Ca <1 cm 9 (14%) 41 (17%) 41 (23%) 31 (12%) 41 (16%) 65 (14%) 371 (27%) <0.001
>1 cm 57 (86%) 201 (83%) 134 (77%) 223 (88%) 209 (84%) 389 (86%) 985 (73%)
pN Stage N0 35 (53%) 90 (37%) 87 (50%) 155 (61%) 146 (58%) 270 (60%) 936 (69%) <0.001
N1 31 (47%) 152 (63%) 88 (50%) 99 (39%) 104 (42%) 184 (40%) 420 (31%)
M Stage M0 63 (96%) 229 (95%) 168 (96%) 248 (98%) 243 (97%) 436 (96%) 1322 (98%) 0.224
M1 3 (4%) 13 (5%) 7 (4%) 6 (2%) 7 (3%) 18 (4%) 34 (2%)
GAMES risk
group
Low 19 (29%) 118 (49%) 84 (48%) 117 (46%) 116 (47%) 154 (34%) 422 (31%) <0.001
Int 24 (36%) 53 (22%) 44 (25%) 78 (31%) 86 (34%) 189 (42%) 628 (46%)
High 23 (35%) 71 (29%) 47 (30%) 59 (23%) 47 (19%) 111 (24%) 306 (23%)
RRA No 66 (100%) 241 (>99%) 172 (98%) 232 (91%) 198 (79%) 357 (79%) 657 (49%) <0.001
Yes 0 (0%) 1 (<1%) 3 (2%) 22 (9%) 52 (21%) 97 (21%) 699 (51%)
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decades.15,16 The incidence and presenting features of this common
disease have undergone signiﬁcant changes in recent times. It is
now recognized that the incidence of papillary thyroid carcinoma is
rising at a faster rate than any other malignancy.17 The reasons
proposed for this are contentious. There is no doubt that enhanced
imaging has resulted in increased rates of detection, particularly of
cancers less than 1 cm in size (microcarcinomas).3,17 However,
there has also been an increase in tumors greater than 4e6 cm,
suggesting that the increasing incidence may be a true increase
caused by other yet unknown factors.18 Thyroid cancer is recog-
nized as being more common in females. However, recent reports
suggest the incidence in women may be increasing at a higher rate
than in males.4 The incidence has also been reported to be
increasing at a faster rate in older patients.17
Early reports of deaths fromWDTC suggested that less than total
thyroidectomy procedures resulted in less favorable oncological
outcomes, and that all gross disease should be removed as part of
the initial surgical procedure.19e21 Debate about the required
extent of initial surgical therapy continues, with an understanding
that thyroid lobectomy is a safe and effective option in low risk,
unifocal, intraglandular thyroid cancers9e11,22 The management of
the contralateral lobe in low risk cases has been long debated with
evidence supporting both lobectomy alone23,24 and total thyroid-
ectomy.25,26 In the absence of prospective randomized controlledTable 3
Analysis of DSS by decade.
Decade Number
(n ¼ 2797)
10 yr DSS% p Value






1996e2005 1356 96.1trials, this debate is unlikely to be resolved. In high risk cases, the
place of total thyroidectomy is widely accepted.
Over the past 8 decades at MSKCC there has been an increase in
the rate of total thyroidectomy (Fig. 2). High resolution ultrasound
imaging in the pre-operative investigation of patients with WDTC
has increased the number of contralateral thyroid nodules identi-
ﬁed preoperatively. This, previously considered occult disease, now
results in total thyroidectomy rather than thyroid lobectomy being
adopted, even in low risk patients. Surgical practice has therefore
gone full circle, with an initial move away from total thyroidectomy
to thyroid lobectomy for selected low risk cases with now a move
back towards total thyroidectomy to excise previously occult
contralateral nodular disease, regardless of its histological status.
The role of RRA also remains unclear in certain situations. For
low risk patients, little beneﬁt has been demonstrated,27,28 whereas
in high risk cases the beneﬁts are more certain.28 The therapeutic
efﬁcacy of RRA in the management of WDTC has led to a large
increase in its use, even in low risk patients, at many major centers
across the US.29
Our results over the past 73 years reﬂect the changes described
above, with an increasing number of cases managed within our
institution over the past 8 decades (Fig. 1). Along with this volume
increase, we have also observed a trend towards an older patient
group (94% versus 53%, p < 0.001), with a higher percentage of
women represented in recent years (72% versus 68%, p ¼ 0.026)
(Table 2). These trends may be due to a change in referral patterns
with increased access to ultrasound in both primary care and
obstetrics and gynecology practice. Analysis of survival of the
whole group conﬁrms our earlier reports that non-papillary
histology, age over 45 years, the presence of distant metastases,
extrathyroid extension, and size over 4 cm are predictive of poorer
DSS. The results of analysis of both patient and tumor related
factors underscore the importance of risk stratiﬁcation, to allow for
individualization in the management of WDTC (Table 5).
In terms of histopathological subtypes of WDTC, papillary
thyroid carcinoma remains the most prevalent, with an increasing
percentage in recent years (92% versus 78%, p < 0.001). There has
Table 4a









Risk group Low 1030 (37%) 254 (45%) 251 (43%) 525 (32%) <0.001
Intermediate 1102 (39%) 149 (26%) 217 (37%) 736 (45%)
High 664 (24%) 161 (29%) 116 (20%) 387 (23%)
Fig. 1. Patient numbers managed by decade.
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16% to 5% (p< 0.001). This is likely due to the recognition thatmany
primary lesions previously described as follicular carcinoma are
now categorized as follicular variant of papillary carcinoma. A
further change in histological reporting has resulted in the recog-
nition of poorly differentiated thyroid carcinoma. Towards the end
of our study this was recognized as a separate histological entity,
and was reported separately. Although we found a relatively
constant rate of pT4 disease presented throughout the decades,
somemore recent pT4 cancers may have been recognized as poorly
differentiated and therefore excluded from this analysis. In keeping
with other reports, we also noted a signiﬁcant increase in the
number of microcarcinomas (<1 cm). pT1 disease comprised 48% of
the recent cohort of patients compared to 19% of the earlier cohort,
p < 0.001. Interestingly, nodal disease has decreased in prevalence,
from 48% to 33% (p < 0.001). This may be due to the increase in
early T stage tumors that we now see. It may also be due to a change
in neck dissection policy since our risk stratiﬁcation system was
introduced, with neck dissection only being carried out for clini-
cally palpable neck disease in the past, and more recently forTable 4b
10 Year DSS stratiﬁed by GAMES group and by time period.
Number (%) 1932e1969
10 Yr DSS (n ¼ 564
Risk group Low 1030 (37%) 98.0%
Intermediate 1102 (39%) 93.0%
High 664 (24%) 63.6%radiographically detected lymph node metastases. The percentage
of patients presenting with evidence of distant metastases has
remained constant at less than 5%, suggesting that the percentage
of patients presenting with aggressive, high risk disease that is
likely to affect survival has not changed dramatically over the 7
decade period.
With regards to our risk stratiﬁcation system (GAMES), we
observed a shift of low risk cases to the intermediate risk group
category (Table 4a). This is as a result of the older patient age at
presentation, despite the increases in low risk tumors. Only 25% of
patients in the earlier cohort underwent total thyroidectomy versus
68% in the recent cohort. In our institution, even older patients with
intraglandular WDTC are selected for thyroid lobectomy. Therefore
a change in overall risk stratiﬁcation should have a limited effect on
rates of total thyroidectomy. This change in practice therefore is
likely to be multifactorial in etiology. Along with the change in risk
groups, the introduction of preoperative ultrasound over this time
period has resulted in more occult nodular disease in the contra-
lateral lobe being detected. As a consequence, there has been an
increase in the number of total thyroidectomies. In addition, the)
1970e1989
10 Yr DSS (n ¼ 584)
1990e2005






Univariate analysis for disease speciﬁc survival for the groups as a whole.
Variable Group Number 10 Yr DSS p Value Multivariate analysis
HR 95% CI p
Age <45 1396 (50%) 98.4% <0.001 Referent
>45 1401 (50%) 87.5% 4.987 2.899e8.272 <0.001
Gender Female 1966 (70%) 94.8% <0.001 Referent
Male 831 (30%) 89.4% 1.529 10.47e2.231 0.028
Procedure Thyroid lobectomy 1223 (44%) 94.6% <0.001
Thyroid isthmusectomy 20 (1%) 100.0%
Subtotal thyroidectomy 69 (2%) 90.1%
Total thyroidectomy 1482 (53%) 91.8%
Unresectable thyroid Ca 3 (0%) 0.0%
Histology Papillary carcinoma 2443 (87%) 94.8% <0.001 Referent
Hurthle cell carcinoma 115 (4%) 82.8% 1.995 1.172e3.395 0.011
Follicular carcinoma 239 (9%) 84.4% 2.852 1.577e5.156 0.001
pT Stage T1 1042 (37%) 97.7% 0.000
T2 933 (34%) 94.7%
T3 613 (22%) 91.5%
T4 198 (7%) 68.3%
Size of tumor <4 cm 2228 (88%) 96.9% 0.000 Referent
>4 cm 310 (12%) 79.3% 3.713 2.521e5.469 <0.001
Micro carcinoma <1 cm 599 (21%) 98.2% 0.000
>1 cm 2198 (79%) 92.0%
Any extrathyroid
extension
Absent 2198 (79%) 94.9% 0.000 Referent
Present 598 (21%) 85.8% 2.892 1.916e4.266 <0.001
pN Stage N0 1719 (62%) 94.0% 0.292
N1 1078 (38%) 92.1%
M Stage M0 2709 (97%) 95.1% 0.000 Referent
M1 88 (3%) 41.7% 11.307 7.452e17.157 <0.001
Risk group Low 1030 (37%) 99.4% 0.000
Intermediate 1102 (39%) 96.0%
High 664 (24%) 78.8%
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for by several international guidelines now recommending total
thyroidectomy for intra-thyroid lesions over 1.5 cm.9e11
Post-operative adjuvant RRAwas rarely used in the early part of
this study, but has become a part of therapy for 44% of cases in
recent times (Fig. 2). Over the past few years we have becomeFig. 2. Percentage of patients undergoing total thyroidectomincreasingly aware of the side effects of RRA as well as the risk of
second primaries. As a result, we now carefully consider the risk
versus beneﬁt ratio before recommending treatment with RRA.
DSS for patients managed during this study has increased
signiﬁcantly from below 90% to over 95% in the later years (Table 3).
This improvement is in keeping with other series and demonstratesy, receiving RRA and disease speciﬁc survival by decade.
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rience. Careful scrutiny of these ﬁgures however demonstrates that
these improvements were largely achieved prior to the mid-1970s
(Table 4b). It was at this time that evidence to support the surgical
techniques now routinely employed was starting to appear. This is
with particular reference to abandoning the practice of subtotal or
near total thyroidectomy and instituting the practice of routine
“extracapsular” total thyroidectomy. Around this time the under-
standing of risk stratiﬁcation was improving with several investi-
gators presenting their own method for predicting outcome in
patients with WDTC.27,30,31 More recently, despite the increase in
the rates of total thyroidectomy and RRA, no signiﬁcant improve-
ment in DSS has been observed for a cancer which already had
excellent outcomes (Fig. 2). These ﬁgures are affected by the
changing trends in presentation. An increased number of inter-
mediate risk cases are now seen (Table 4a). Analysis on a risk group
speciﬁc level shows improvement in each time period studies
(Table 4b) although overall, improved survival was more marked
from the mid 1970s.
Over the past 8 decades in our institution, the incidence,
presentation and management of WDTC has changed considerably.
Older patients with earlier stage disease present an increasing
workload for our department. It is likely that the incidence ofWDTC
will continue to rise in the short to medium term at least. Already
excellent outcomes are unlikely to be signiﬁcantly improved with
an ever more aggressive approach to treatment. Opportunities to
improve standards of care include identifying patient groups most
likely to beneﬁt from aggressive contemporary management and at
the same time developing new therapeutic strategies. Efforts must
also include attempts to identify those patients who will beneﬁt
from less invasive treatment, which would reduce the potential
lifelong impact that complications of therapy can have, whilst
maintaining oncological outcomes and allowing focusing of
resources on those patients most likely to beneﬁt. Our efforts in
clinical care in future need to be focused to reducing mortality from
thyroid cancer, and in the discovery of new treatment modalities,
that will create a positive impact on patients with distant meta-
static disease, for whom we have little to offer at this time.
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